共 50 条
- [31] NMS-P293, a novel potent and selective PARP-1 inhibitor with high antitumor efficacy and tolerability[J]. CANCER RESEARCH, 2016, 76Montagnoli, AlessiaRainoldi, SoniaCiavolella, AntonellaBallinari, DarioCaprera, FrancescoCeriani, LucioLupi, RositaCiomei, MarinaFelder, EduardIsacchi, AntonellaDonati, DanieleGalvani, ArturoPapeo, Gianluca
- [32] ON 123300, an orally administered novel CDK4/6+ARK5 inhibitor, exhibits potent antitumor activity in vivo: comparative studies with Palbociclib[J]. CANCER RESEARCH, 2017, 77Patel, ShraddhaPancholi, PriyaVisal, TanviSamant, AmrutaKansara, DhvanirRajadhyaksha, V. J.Hoffman, Benjamin S.Maniar, ManojSehdev, Vikas
- [33] Discovery of novel, potent, selective and orally bioavailable HPK1 inhibitor for enhancing the efficacy of anti-PD-L1 antibody[J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 267Zeng, ShenxinWu, MingfeiJin, YuyuanYe, YingqiaoXia, HeyeChen, XinyiChe, JinxinWang, ZunyuanWu, YingDong, XiaowuChen, YinqiaoHuang, Wenhai
- [34] Inhibition of Wee1, AKT, and CDK4 Underlies the Efficacy of the HSP90 Inhibitor XL888 in an In Vivo Model of NRAS-Mutant Melanoma[J]. MOLECULAR CANCER THERAPEUTICS, 2013, 12 (06) : 901 - 912Haarberg, H. EirikParaiso, Kim H. T.Wood, ElizabethRebecca, Vito W.Sondak, Vernon K.Koomen, John M.Smalley, Keiran S. M.
- [35] Preclinical anti-tumor efficacy and mode of action of a novel, orally available, selective MKNK1 inhibitor [BAY 1143269][J]. CANCER RESEARCH, 2015, 75Santag, SusannSiegel, FranziskaWegner, Antje MargretSchneider, ClaudiaBoemer, UlfEis, KnutPuehler, FlorianMichels, Martinvon Nussbaum, FranzZiegelbauer, KarlMumberg, DominikPetersen, Kirstin
- [36] In vitro characteristics, anticoagulant effects and in vivo antithrombotic efficacy of a novel, potent and orally active direct factor Xa inhibitor, DU-176b.[J]. BLOOD, 2004, 104 (11) : 515A - 515AMorishima, YFurugohri, TIsobe, KHonda, YMatsumoto, CShiozaki, YMuramatsu, SSugiyama, NShibano, T
- [37] Discovery of a novel, potent and selective small-molecule inhibitor of PD-1/PD-L1 interaction with robust in vivo anti-tumour efficacy[J]. BRITISH JOURNAL OF PHARMACOLOGY, 2021, 178 (13) : 2651 - 2670Liu, ChenglongZhou, FeilongYan, ZiqinShen, LianZhang, XichenHe, FenglianWang, HengLu, XiaojieYu, KerZhao, YujunZhu, Di
- [38] Development of highly selective, potent, orally available PIM1 inhibitor BLX0631 shows a therapeutics potential in multiple myeloma models[J]. CANCER RESEARCH, 2024, 84 (06)Li, ZhaoangLin, ChenyuBearss, David J.Vankayalapati, Hariprasad
- [39] NMS-E668, a highly potent orally available RET inhibitor with selectivity towards VEGFR2 and demonstrated antitumor efficacy in multiple RET-driven cancer models[J]. CANCER RESEARCH, 2018, 78 (13)Ardini, ElenaBanfi, PatriziaAvanzi, NillaCiomei, MarinaPolucci, PaoloCirla, AlessandraD'Anello, MatteoBorgia, Andrea LombardiMotto, IlariaCristiani, CinziaBallinari, DarioFelder, EduardDonati, DanieleGalvani, ArturoIsacchi, AntonellaMenichincheri, Maria
- [40] KW-2450, a novel orally-active dual IGF1R/IR inhibitor: Antitumor effects in vitro and in vivo[J]. CANCER RESEARCH, 2011, 71Maekawa, YoshimiKoizumi, FumitoKashima, NaomiSuzuki, MasayoUmehara, HiroshiTakahashi, HirokoNakamura, HiroakiNara, ShinjiNakazato, TomoyukiKanda, YutakaTakahashi, TakeshiAkinaga, ShiroShiotsu, YukimasaSoga, Shiro